Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
Attention deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in children and adolescents, and in about half of these patients, significant symptomology continues into adulthood. Although impulsivity and hyperactivity are the most salient features of ADHD, cognitive deficits, particularly impairments in attention and executive function, are an important component, particularly in adolescents and adults, with over 90% of adults seeking treatment for ADHD manifesting cognitive dysfunction. Currently available medications treat the core ADHD symptoms but typically do not adequately address cognitive aspects of ADHD, underscoring the need for new therapeutics. Dopamine and norepinephrine are hypothesized to be particularly important in ADHD, but there is emerging evidence that cholinergic neurotransmission, particularly involving neuronal nicotinic acetylcholine receptors (nAChRs), may play a role in the pathophysiology of ADHD. Nicotine has demonstrated procognitive effects in both humans and experimental animals and has produced signals of efficacy in small proof-of-concept adult ADHD trials. Although adverse effects associated with nicotine preclude its development as a therapeutic, a number of novel nAChR agonists with improved safety/tolerability profiles have been discovered. Of these, ABT-418 and ABT-089 have both demonstrated signals of efficacy in adults with ADHD. Notably, tolerability issues that might be expected of a nAChR agonist, such as nausea and emesis, were not observed at efficacious doses of ABT-089. Further understanding of the effects of novel neuronal nAChR agonists on specific aspects of cognitive functioning in ADHD is required to assess the full potential of this approach.
Wilens
Timothy E
TE
Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, Yawkey Center for Outpatient Care-YAW 6A, Boston, MA 02114, USA. twilens@partners.org
Decker
Michael W
MW
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission
D007555:Isoxazoles; D018722:Nicotinic Agonists; D011725:Pyridines; D011759:Pyrrolidines; D011978:Receptors, Nicotinic; C088383:3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; C108326:pozanicline
Behav Brain Res. 2006 Dec 15;175(2):201-11
17081628
Eur J Pharmacol. 1987 Sep 23;141(3):395-9
3666033
J Subst Abuse. 1995;7(3):373-8
8749796
J Child Psychol Psychiatry. 1996 Jan;37(1):51-87
8655658
Psychopharmacology (Berl). 1999 Mar;142(4):334-42
10229057
J Am Acad Child Adolesc Psychiatry. 1995 Mar;34(3):336-47
7896676
Curr Med Chem. 2006;13(13):1567-84
16787204
Annu Rev Pharmacol Toxicol. 2002;42:135-63
11807168
Life Sci. 1995;56(8):545-70
7869835
J Child Psychol Psychiatry. 1977 Apr;18(2):137-65
326801
Arch Neurol. 1990 Aug;47(8):919-26
2375699
Biol Psychiatry. 1999 Jun 15;45(12):1542-52
10376114
Psychopharmacology (Berl). 2000 Apr;149(3):293-305
10823411
Annu Rev Neurosci. 1993;16:403-43
7681637
Neuropsychopharmacology. 2007 Jan;32(1):17-34
16936709
JAMA. 1998 Apr 8;279(14):1100-7
9546570
Psychopharmacology (Berl). 1984;82(4):338-42
6427826
Psychopharmacology (Berl). 1998 Mar;136(1):50-8
9537682
Neuropsychopharmacology. 2002 Sep;27(3):479-97
12225705
N Engl J Med. 1999 Jan 7;340(1):40-6
9878644
Prog Neurobiol. 2004 Dec;74(6):363-96
15649582
Arch Gen Psychiatry. 1996 May;53(5):437-46
8624187
Arch Gen Psychiatry. 1993 Jul;50(7):565-76
8317950
Neurobehav Toxicol Teratol. 1982 May-Jun;4(3):365-9
7099355
Behav Brain Res. 2002 Mar 10;130(1-2):3-28
11864714
Am J Psychiatry. 1998 Oct;155(10):1358-64
9766767
Arch Gen Psychiatry. 1975 Jun;32(6):790-5
1093506
J Child Adolesc Psychopharmacol. 2005 Dec;15(6):996-1004
16379520
Psychopharmacology (Berl). 2003 Jul;168(3):271-9
12698230
J Nerv Ment Dis. 1979 May;167(5):288-97
448331
Arch Gen Psychiatry. 2001 Mar;58(3):289-95
11231836
J Atten Disord. 2002 Mar;5(4):203-9
11967476
Psychopharmacology (Berl). 2004 Nov;176(2):182-94
15083253
Am J Psychiatry. 1999 Dec;156(12):1931-7
10588407
Nicotine Tob Res. 2006 Feb;8(1):37-47
16497598
CNS Drugs. 2004;18(6):397-401
15089111
World Psychiatry. 2003 Jun;2(2):104-13
16946911
Psychopharmacology (Berl). 1996 Jan;123(1):55-63
8741955
J Clin Psychiatry. 1998;59 Suppl 7:17-23
9680049
J Pharmacol Exp Ther. 1997 Oct;283(1):235-46
9336329
Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39
16220335
J Abnorm Child Psychol. 1995 Aug;23(4):411-37
7560554
Psychiatry Res. 1995 Jan 31;56(1):59-70
7792343
Am J Psychiatry. 2006 Oct;163(10):1730-8
17012683
Psychopharmacology (Berl). 1984;84(2):205-16
6438679
CNS Drug Rev. 2004 Summer;10(2):167-82
15179445
J Am Acad Child Adolesc Psychiatry. 1990 Jul;29(4):546-57
2387789
J Clin Psychopharmacol. 1999 Jun;19(3):257-64
10350032
Behav Neurosci. 1987 Aug;101(4):457-64
2820435
Compr Psychiatry. 1980 Sep-Oct;21(5):358-69
6774849
Am J Psychiatry. 1994 May;151(5):665-9
8166306
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9596-601
12876201
Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:50-61
8534424
Psychopharmacology (Berl). 1995 Jun;119(4):368-75
7480515
Pharmacol Ther. 1983;21(2):189-208
6353441
J Child Neurol. 1993 Oct;8(4):339-47
8228029
J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):886-96
7649959
Physiol Behav. 2006 Mar 30;87(3):614-24
16466655
J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S
11833633
Prog Neurobiol. 2002 Dec;68(5):341-60
12531234
J Child Psychol Psychiatry. 1995 Nov;36(8):1459-73
8988278
J Psychopharmacol. 2007 Mar;21(2):171-8
17329297
Int Clin Psychopharmacol. 1986 Jan;1(1):45-52
3549871
J Learn Disabil. 1991 Dec;24(10):630-6
1783870
Neuroscience. 2004;129(1):11-24
15489024
J Consult Clin Psychol. 1997 Feb;65(1):150-160
9103744
Psychopharmacology (Berl). 1989;97(2):257-61
2498936
Clin Neuropsychol. 1999 Feb;13(1):12-21
10937644
Brain Res Brain Res Rev. 2005 Feb;48(1):98-111
15708630
Am J Psychiatry. 2001 Jul;158(7):1052-7
11431226
J Abnorm Child Psychol. 1991 Feb;19(1):35-52
2030246
CNS Drug Rev. 2004 Summer;10(2):147-66
15179444
Synapse. 1991 Feb;7(2):151-68
1672782
Pharmacol Biochem Behav. 2005 Nov;82(3):539-48
16360813
J Am Acad Child Psychiatry. 1985 Mar;24(2):211-20
3989165
J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):37-44
9000779
Psychopharmacol Bull. 1996;32(1):67-73
8927677
Trends Pharmacol Sci. 2000 Jun;21(6):211-7
10838608
J Neurosci. 2002 Mar 1;22(5):1905-13
11880520
J Med Chem. 2006 Jul 13;49(14):4374-83
16821797
J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):754-63
9183129
J Abnorm Child Psychol. 1995 Dec;23(6):729-49
8609310
J Clin Exp Neuropsychol. 2000 Feb;22(1):115-24
10649550
J Am Acad Child Adolesc Psychiatry. 1995 Aug;34(8):1015-24
7665440
Pediatrics. 1987 Oct;80(4):491-501
3658567
Mol Psychiatry. 2003 Jan;8(1):103-8
12556914
J Atten Disord. 2009 Sep;13(2):161-7
19420282
J Atten Disord. 2002 Mar;5(4):189-202
11967475
Gen Pharmacol. 1983;14(3):321-5
6135645
Trends Pharmacol Sci. 2006 Sep;27(9):482-91
16876883
Psychopharmacology (Berl). 1988;95(2):171-5
3137593
Child Psychiatry Hum Dev. 1986 Summer;16(4):221-34
3743175
Int J Neuropsychopharmacol. 2002 Jun;5(2):111-3
12135534
Brain Res. 1996 Apr 1;714(1-2):185-91
8861624
Biol Psychiatry. 2006 Jun 1;59(11):1065-70
16499880
J Consult Clin Psychol. 1990 Oct;58(5):580-8
2254504
JAMA. 2004 Aug 4;292(5):619-23
15292088
Pediatrics. 1989 Oct;84(4):648-57
2780127
J Pediatr. 1981 Jun;98(6):912-5
7229792
Psychol Bull. 1997 Jan;121(1):65-94
9000892
Neurosci Lett. 2006 Dec 13;410(1):15-9
17055644
Trends Neurosci. 1997 Feb;20(2):92-8
9023878
J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70
16190797
Am J Psychiatry. 1994 Dec;151(12):1791-6
7977887
Annu Rev Pharmacol Toxicol. 2004;44:269-96
14744247
Arch Clin Neuropsychol. 1999 Feb;14(2):217-33
14590604
Brain Res Brain Res Rev. 1998 May;26(2-3):198-216
9651527
J Clin Psychol. 1989 Jul;45(4):619-32
2768502
Am J Psychiatry. 2000 Jan;157(1):4-15
10618007
N Engl J Med. 1990 Nov 15;323(20):1361-6
2233902
Can J Psychiatry. 1986 Aug;31(6):557-67
3756759
J Child Psychol Psychiatry. 2002 Sep;43(6):785-96
12236613
Biol Psychiatry. 1998 Aug 15;44(4):260-8
9715357
Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):573-603, viii
10944658
J Consult Clin Psychol. 2000 Jun;68(3):477-488
10883564
Psychopharmacology (Berl). 2004 Apr;172(4):375-83
14727003
Neuropsychopharmacology. 2004 Jul;29(7):1378-85
15138435
Psychopharmacology (Berl). 1992;108(4):485-94
1410164
Cereb Cortex. 1998 Mar;8(2):164-72
9542895
J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):877-85
7649958
J Clin Psychiatry. 1998;59 Suppl 7:4-16
9680048
J Med Chem. 2006 Jul 13;49(14):4425-36
16821801
Neuropharmacology. 2003 Jun;44(8):1054-67
12763099
J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1222-7
9291723
Psychol Med. 1999 May;29(3):527-38
10405075
Am J Psychiatry. 1996 Sep;153(9):1138-42
8780415
Arch Gen Psychiatry. 2005 Oct;62(10):1142-7
16203959
Am J Psychiatry. 2000 May;157(5):816-8
10784477
J Pharmacol Exp Ther. 1997 Oct;283(1):247-58
9336330
Am J Psychiatry. 1993 Dec;150(12):1792-8
8238632
Compr Psychiatry. 1990 Sep-Oct;31(5):416-25
2225800
J Abnorm Child Psychol. 1989 Oct;17(5):473-91
2681316
Pharmacol Biochem Behav. 1989 May;33(1):1-6
2780768